EMEA-002243-PIP01-17-M04 - paediatric investigation plan

Eptinezumab

Key facts

• Invented name:
  Vyepti
• Active Substance:
  Eptinezumab
• Therapeutic area:
  Neurology
• Decision number:
  P/0399/2023
• PIP number:
  EMEA-002243-PIP01-17-M04
• Pharmaceutical form(s):
  Concentrate for solution for infusion
• Condition(s) / indication(s):
  Prevention of migraine headaches
• Route(s) of administration:
  Intravenous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  27/10/2023

Decision

P/0399/2023 : EMA decision of 27 October 2023 on the acceptance of a modification of an agreed paediatric investigation plan for eptinezumab (Vyepti), (EMEA-002243-PIP01-17-M04)

AdoptedReference Number: EMA/400367/2023